Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 2/3 2Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 104Colorectal Neoplasms 63Stomach Neoplasms 49Rectal Neoplasms 42Colonic Neoplasms 24Neoplasm Metastasis 21Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Pancreatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 12Neoplasms 12Gallbladder Neoplasms 7Cholangiocarcinoma 7Adenocarcinoma 6Esophageal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Esophageal Squamous Cell Carcinoma 4Neuroendocrine Tumors 3Gastrointestinal Neoplasms 3Digestive System Neoplasms 3Bile Duct Neoplasms 3Recurrence 2Pathologic Complete Response 2Liver Neoplasms 2Intestinal Neoplasms 2Hand-Foot Syndrome 2HER2-positive Advanced Breast Cancer 2HER2 Positive Metastatic Breast Cancer 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Cisplatin 21Radiotherapy 16Fluorouracil 16Paclitaxel 14Irinotecan 7Docetaxel 7Neoadjuvant Therapy 6Drug Therapy 5tislelizumab 4sintilimab 4Surgical Procedures, Operative 4Radiation 4Oxaliplatin 4Leucovorin 4Esophagectomy 4Capecitabine 4toripalimab 3pembrolizumab 3TP protocol 3Chemotherapy, Adjuvant 3S 1 (combination) 2Levoleucovorin 2Cetuximab 2Carboplatin 2lenvatinib 1irinotecan sucrosofate 1durvalumab 1atropine sulfate-diphenoxylate hydrochloride drug combination 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Squamous Cell Carcinoma × Capecitabine × Clear all
NCT04550260 2026-05-13

KUNLUN

AstraZeneca

Phase 3 Active not recruiting
640 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07177794 2026-04-21

EC-CRT-008

Sun Yat-sen University

Phase 3 Recruiting
242 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeiGene

Phase 3 Completed
649 enrolled 22 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05737563 2024-01-23

Escape

Sun Yat-sen University

Phase 3 Unknown
380 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡